Last reviewed · How we verify
NCT04252612
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
EARLY_PHASE1 trial testing Pramlintide in Cutaneous Squamous Cell Carcinoma. Withdrawn.
26 June 2023
Quick facts
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Start date | 30 January 2020 |
| Primary completion | 26 June 2023 |
| Estimated completion | 26 June 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Pramlintide (PRAMLINTIDE) — full drug profile →
Conditions studied
- Cutaneous Squamous Cell Carcinoma — all drugs for Cutaneous Squamous Cell Carcinoma →
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Who can join
18 and older, any sex, with Cutaneous Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will treat resectable cutaneous squamous cell carcinoma patients with pramlintide for two weeks prior to surgical resection of their tumor. Pre-treatment and surgical resection specimens will then be analyzed for biological alterations.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04252612
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pramlintide
Trials testing the same drug.
- NCT06186063 — The Role of Amylin in Bone Metabolism · NA · unknown
- NCT05199714 — A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes · NA · completed
Other recruiting trials for Cutaneous Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
- NCT07402616 — Ex Vivo Cutaneous SCC · NA · recruiting
- NCT06875609 — ctDNA in Cutaneous Squamous Cell Carcinoma · recruiting
- NCT06567314 — Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma · Phase 2 · recruiting
- NCT06659146 — Thermotherapy in Addition to SOC Palliative Radiotherapy · NA · recruiting
Other H. Lee Moffitt Cancer Center and Research Institute trials
Trials by the same sponsor.
- NCT05041335 — Wet Heparinized Suction for Abdominal Cancer · NA · not yet recruiting
- NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs · NA · recruiting
- NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors · Phase 1 · recruiting
- NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma · Phase 2 · recruiting
- NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04252612 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
- Last refreshed: 28 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04252612.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing